A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios

Frédéric M. Vaz, Albert H. Bootsma, Willem Kulik, Aad Verrips, Ron A. Wevers, Peter C. Schielen, Andrea De Barber, Hidde H. Huidekoper

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cerebrotendinous xanthomatosis (CTX) is a treatable neurodegenerative metabolic disorder of bile acid synthesis in which symptoms can be prevented if treatment with chenodeoxycholic acid supplementation is initiated early in life, making CTX an excellent candidate for newborn screening. We developed a new dried blood spot (DBS) screening assay for this disorder on the basis of different ratios between the accumulating cholestanetetrol glucuronide (tetrol) and specific bile acids/bile acid intermediates, without the need for derivatization. A quarter-inch DBS punch was extracted with methanol, internal standards were added, and after concentration the extract was injected into the tandem mass spectrometer using a 2 min flow injection analysis for which specific transitions were measured for cholestanetetrol glucuronide, taurochenodeoxycholic acid (t-CDCA), and taurotrihydroxycholestanoic acid (t-THCA). A proof-of-principle experiment was performed using 217 Guthrie cards from healthy term/preterm newborns, CTX patients, and Zellweger patients. Using two calculated biomarkers, tetrol:t-CDCA and t-THCA:tetrol, this straightforward method achieved an excellent separation between DBSs of CTX patients and those of controls, Zellweger patients, and newborns with cholestasis. The results of this small pilot study indicate that the tetrol:t-CDCA ratio is an excellent derived biomarker for CTX that has the potential to be used in neonatal screening programs.

Original languageEnglish (US)
Pages (from-to)1002-1007
Number of pages6
JournalJournal of Lipid Research
Volume58
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Cholestanols
Taurochenodeoxycholic Acid
Cerebrotendinous Xanthomatosis
Glucuronides
Metabolites
Bile Acids and Salts
Screening
Newborn Infant
Biomarkers
Blood
Chenodeoxycholic Acid
Acids
Mass spectrometers
Methanol
Assays
Flow Injection Analysis
Neonatal Screening
Cholestasis
Neurodegenerative Diseases
Experiments

Keywords

  • Bile acid metabolism
  • Bile acids and salts biosynthesis
  • CYP27A1
  • Inborn errors of metabolism
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

Vaz, F. M., Bootsma, A. H., Kulik, W., Verrips, A., Wevers, R. A., Schielen, P. C., ... Huidekoper, H. H. (2017). A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios. Journal of Lipid Research, 58(5), 1002-1007. https://doi.org/10.1194/jlr.P075051

A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios. / Vaz, Frédéric M.; Bootsma, Albert H.; Kulik, Willem; Verrips, Aad; Wevers, Ron A.; Schielen, Peter C.; De Barber, Andrea; Huidekoper, Hidde H.

In: Journal of Lipid Research, Vol. 58, No. 5, 01.05.2017, p. 1002-1007.

Research output: Contribution to journalArticle

Vaz, FM, Bootsma, AH, Kulik, W, Verrips, A, Wevers, RA, Schielen, PC, De Barber, A & Huidekoper, HH 2017, 'A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios', Journal of Lipid Research, vol. 58, no. 5, pp. 1002-1007. https://doi.org/10.1194/jlr.P075051
Vaz, Frédéric M. ; Bootsma, Albert H. ; Kulik, Willem ; Verrips, Aad ; Wevers, Ron A. ; Schielen, Peter C. ; De Barber, Andrea ; Huidekoper, Hidde H. / A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios. In: Journal of Lipid Research. 2017 ; Vol. 58, No. 5. pp. 1002-1007.
@article{1c09078c4a8241149981f9f21ca55878,
title = "A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios",
abstract = "Cerebrotendinous xanthomatosis (CTX) is a treatable neurodegenerative metabolic disorder of bile acid synthesis in which symptoms can be prevented if treatment with chenodeoxycholic acid supplementation is initiated early in life, making CTX an excellent candidate for newborn screening. We developed a new dried blood spot (DBS) screening assay for this disorder on the basis of different ratios between the accumulating cholestanetetrol glucuronide (tetrol) and specific bile acids/bile acid intermediates, without the need for derivatization. A quarter-inch DBS punch was extracted with methanol, internal standards were added, and after concentration the extract was injected into the tandem mass spectrometer using a 2 min flow injection analysis for which specific transitions were measured for cholestanetetrol glucuronide, taurochenodeoxycholic acid (t-CDCA), and taurotrihydroxycholestanoic acid (t-THCA). A proof-of-principle experiment was performed using 217 Guthrie cards from healthy term/preterm newborns, CTX patients, and Zellweger patients. Using two calculated biomarkers, tetrol:t-CDCA and t-THCA:tetrol, this straightforward method achieved an excellent separation between DBSs of CTX patients and those of controls, Zellweger patients, and newborns with cholestasis. The results of this small pilot study indicate that the tetrol:t-CDCA ratio is an excellent derived biomarker for CTX that has the potential to be used in neonatal screening programs.",
keywords = "Bile acid metabolism, Bile acids and salts biosynthesis, CYP27A1, Inborn errors of metabolism, Tandem mass spectrometry",
author = "Vaz, {Fr{\'e}d{\'e}ric M.} and Bootsma, {Albert H.} and Willem Kulik and Aad Verrips and Wevers, {Ron A.} and Schielen, {Peter C.} and {De Barber}, Andrea and Huidekoper, {Hidde H.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1194/jlr.P075051",
language = "English (US)",
volume = "58",
pages = "1002--1007",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "5",

}

TY - JOUR

T1 - A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios

AU - Vaz, Frédéric M.

AU - Bootsma, Albert H.

AU - Kulik, Willem

AU - Verrips, Aad

AU - Wevers, Ron A.

AU - Schielen, Peter C.

AU - De Barber, Andrea

AU - Huidekoper, Hidde H.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Cerebrotendinous xanthomatosis (CTX) is a treatable neurodegenerative metabolic disorder of bile acid synthesis in which symptoms can be prevented if treatment with chenodeoxycholic acid supplementation is initiated early in life, making CTX an excellent candidate for newborn screening. We developed a new dried blood spot (DBS) screening assay for this disorder on the basis of different ratios between the accumulating cholestanetetrol glucuronide (tetrol) and specific bile acids/bile acid intermediates, without the need for derivatization. A quarter-inch DBS punch was extracted with methanol, internal standards were added, and after concentration the extract was injected into the tandem mass spectrometer using a 2 min flow injection analysis for which specific transitions were measured for cholestanetetrol glucuronide, taurochenodeoxycholic acid (t-CDCA), and taurotrihydroxycholestanoic acid (t-THCA). A proof-of-principle experiment was performed using 217 Guthrie cards from healthy term/preterm newborns, CTX patients, and Zellweger patients. Using two calculated biomarkers, tetrol:t-CDCA and t-THCA:tetrol, this straightforward method achieved an excellent separation between DBSs of CTX patients and those of controls, Zellweger patients, and newborns with cholestasis. The results of this small pilot study indicate that the tetrol:t-CDCA ratio is an excellent derived biomarker for CTX that has the potential to be used in neonatal screening programs.

AB - Cerebrotendinous xanthomatosis (CTX) is a treatable neurodegenerative metabolic disorder of bile acid synthesis in which symptoms can be prevented if treatment with chenodeoxycholic acid supplementation is initiated early in life, making CTX an excellent candidate for newborn screening. We developed a new dried blood spot (DBS) screening assay for this disorder on the basis of different ratios between the accumulating cholestanetetrol glucuronide (tetrol) and specific bile acids/bile acid intermediates, without the need for derivatization. A quarter-inch DBS punch was extracted with methanol, internal standards were added, and after concentration the extract was injected into the tandem mass spectrometer using a 2 min flow injection analysis for which specific transitions were measured for cholestanetetrol glucuronide, taurochenodeoxycholic acid (t-CDCA), and taurotrihydroxycholestanoic acid (t-THCA). A proof-of-principle experiment was performed using 217 Guthrie cards from healthy term/preterm newborns, CTX patients, and Zellweger patients. Using two calculated biomarkers, tetrol:t-CDCA and t-THCA:tetrol, this straightforward method achieved an excellent separation between DBSs of CTX patients and those of controls, Zellweger patients, and newborns with cholestasis. The results of this small pilot study indicate that the tetrol:t-CDCA ratio is an excellent derived biomarker for CTX that has the potential to be used in neonatal screening programs.

KW - Bile acid metabolism

KW - Bile acids and salts biosynthesis

KW - CYP27A1

KW - Inborn errors of metabolism

KW - Tandem mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=85018915947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018915947&partnerID=8YFLogxK

U2 - 10.1194/jlr.P075051

DO - 10.1194/jlr.P075051

M3 - Article

C2 - 28314860

AN - SCOPUS:85018915947

VL - 58

SP - 1002

EP - 1007

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 5

ER -